source
- Oruka posts Phase 2 win in psoriasis, hoping to compete with SkyriziOruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…Endpoints · 3mo ago↗ source
- Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much asEndpoints · 3mo ago↗ source
- Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialA year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…